Aspartylglucosaminuria

Autosomal_recessive_-_en.svg

Aspartylglucosaminuria (AGU) is a rare autosomal recessive lysosomal storage disorder that affects the glycoprotein degradation pathway. It is characterized by the accumulation of aspartylglucosamine in the lysosomes of various tissues due to a deficiency in the enzyme aspartylglucosaminidase.

Genetics

Aspartylglucosaminuria is caused by mutations in the AGA gene, which encodes the enzyme aspartylglucosaminidase. This enzyme is responsible for breaking down glycoproteins in the lysosomes. The disorder follows an autosomal recessive inheritance pattern, meaning that an individual must inherit two defective copies of the gene, one from each parent, to manifest the disease.

Pathophysiology

The deficiency of aspartylglucosaminidase leads to the accumulation of glycoasparagine in the lysosomes. This accumulation disrupts normal cellular function and leads to the progressive symptoms observed in individuals with AGU. The buildup of these substances primarily affects the central nervous system, but other organs can also be involved.

Clinical Features

Symptoms of aspartylglucosaminuria typically appear in early childhood and progressively worsen over time. Common clinical features include:

• Developmental delay
• Intellectual disability
• Coarse facial features
• Skeletal abnormalities
• Joint stiffness
• Motor dysfunction

Diagnosis

Diagnosis of AGU is based on clinical evaluation, biochemical testing, and genetic testing. Elevated levels of glycoasparagine in the urine can be indicative of the disorder. Genetic testing can confirm the diagnosis by identifying mutations in the AGA gene.

Treatment

Currently, there is no cure for aspartylglucosaminuria. Treatment is primarily supportive and focuses on managing symptoms and improving the quality of life for affected individuals. This may include physical therapy, occupational therapy, and educational support.

Epidemiology

Aspartylglucosaminuria is a rare disorder, with a higher prevalence in certain populations, such as the Finnish population. The incidence in Finland is estimated to be approximately 1 in 18,500 births.

Research

Ongoing research aims to better understand the molecular mechanisms of AGU and to develop potential therapies. Gene therapy and enzyme replacement therapy are areas of active investigation.

See also

• Lysosomal storage disease
• Autosomal recessive disorder
• Glycoprotein
• Enzyme replacement therapy

External links

-